The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Phase III trial of entospletinib is first to evaluate MRD-negative CR as primary endpoint in AML setting
A phase III trial investigating the safety and efficacy of entospletinib for the treatment of patients with newly diagnosed NPM1-mutated acute myeloid leukemia (AML) has been initiated. This trial represents the first in the AML setting to evaluate measurable residual disease (MRD)-negative complete remission (CR) as a primary endpoint.
The trial will recruit approximately 180 adult patients, who will be randomized to receive ≥2 cycles of either entospletinib or placebo, plus conventional induction and consolidation chemotherapy. The primary endpoint is MRD-negative CR, determined using next-generation sequencing (NGS).
Entospletinib is an inhibitor of the oncogene spleen tyrosine kinase (SYK), a key mediator of AML maintenance and progression via the elevated expression of HOXA9 and MEIS1 transcription factors. Aberrations in NPM1 and other AML driver genes have been associated with increased expression of these transcription factors.
In a phase Ib/II trial (NCT02343939), entospletinib in combination with intensive chemotherapy induced higher response rates in patients with NPM1-mutated AML (n = 15; 87%) compared with the entire patient population (n = 53; 70%), and was well tolerated.2
The phase III trial is due to commence mid-2021 and the MRD data anticipated in 2023. For more information on the value of MRD status as a predictor of outcome in patients with NPM1-mutated AML, click here.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content